SCHEMBL1065672

SCHEMBL1065672

O=C(OC(=O)C(F)(F)F)c1ccc(NCCN2CCCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
GLA P06280 1/20 0.47
ATM Q13315 1/20 0.47
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
ALDH1A1 P00352 2/20 0.44
RAB9A P51151 1/20 0.44
ESRRG P62508 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP2D6 P10635 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
AURKA O14965 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TNIK Q9UKE5 1/20 0.41
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291394 0.81 NPSR1 (0.51) EPHX2NPSR1GLAATMESR1
Trifluoroacetic Acid SCHEMBL1065670 0.81 EPHX2 (0.50) EPHX2NPSR1ESR1ESR2ALDH1A1
SCHEMBL5068134 0.80 NPSR1 (0.49) EPHX2NPSR1GLAATMESR1
SCHEMBL1068474 0.78 ESRRG (0.54) EPHX2NPSR1ESR1ESR2ALDH1A1
SCHEMBL27639228 0.78 NPSR1 (0.47) EPHX2NPSR1GLAATMESR1
SCHEMBL30969317 0.77 TNIK (0.51) EPHX2NPSR1GLAATMESR1
SCHEMBL5350540 0.77 ESRRG (0.52) EPHX2NPSR1ESR1ESR2ALDH1A1
SCHEMBL6154983 0.76 TNIK (0.49) EPHX2NPSR1ESR1ESR2ALDH1A1
SCHEMBL23419098 0.74 HRH3 (0.56) EPHX2ATMMEN1KMT2A
SCHEMBL28093052 0.72 CES1 (0.38) RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 EPHX2 3029/4885NPSR1 4455/4885GLA 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.